| Class | Brand | Generic | Indications | Dose Forms | Route | Adult/Ped. Dosing | MOA |
| Aldosterone Receptor Antagonist; K+ Sparing Diuretic | Aldactone | Spironolactone | HTN, Hypokalemia, Ascites, Edema, Aldoseronism | Tablets:
25, 50, 100mg | Oral | 25-400mg
QD
Ped:N/A | Renal competitive aldosterone antagonist; it inhibits the effect of aldosterone by competing for the aldosterone-dependent Na+/K+ exchange site in the distal tubule cells. This increases the secretion of H2O & Na+, while decreasing the excretion of K+ |
| Parenteral Electrolyte
(K+ Supplement) | K-Dur; K-Tab; Klor-Con | Potassium | Hypokalemia, Prophylaxis | K-Dur:
20 mEq ER tablet
K-Tab:
10 mEq ER tablet
Klor-Con:
20 or 25 mEq oral powder for soln.,
8, 10, M10, M20
ER tabs | Oral, IV | 10-100 mEq once to five times daily
Ped: Oral:
3-8 mEq/kg/day
IV:
0.5-0.75 mEq/kg over 1-2 hrs | Electrolyte replenisher that aids in many physiological processes |
| ACE Inhibitor/
Thiazide Combo | Prinzide; Zestoretic | Lisinopril/
Hydrochlorothiazide | HTN | Tablets:
Prinzide: 10/12.5 or 20/25 mg
Zestoretic: 10/12.5, 20/12.5, 20/25mg | Oral | 10/6.25 – 80/50mg
QD
Ped:N/A | diuretic and an antihypertensive agent that lowers elevated blood pressure; ACE inhibitor |
| ARB/Thiazide Combo | Diovan HCT | Valsartan/
Hydrochlorothiazide | HTN | Tablets:
80/12.5, 160/12.5, 160/25, 320/12.5, 320/25mg | Oral | 160/12.5-320/25mg
QD
Ped:N/A | ‘sartan: angiotensin II blocker
HCTZ: increases excretion of Na+ & Cl- (diuretic/antihypertensive) |
| Diuretic | Lasix | Furosemide | HTN,
Edema | Tablets:
20, 40, 80mg
IV/IM Soln.: 10mg/ml
Oral Soln.: 10mg/ml or 40mg/5ml | Oral, IV, IM | 20-80mg
TID-QID
Ped:
1-2mg/kg/day | Anthanilic acid derivative and a potent diuretic that works by blocking the absorption of Na+ and Cl- in the kidney tubules, causing a profound increase in urine output |
| Antineoplastic Agent; Monoclonal Antibody | Rituxan | Rituximab | Non-Hodgkins lymphoma, Rheumatoid Arthritis, Chronic Lymphoid Leukemia | Inj. Soln.:
10mg/ml | IV | 375mg/m(2), usually given as part of a scheduled regiment with other meds
Ped:N/A | MAB that binds to antigen CD20, this disrupts the cell cycle of B-cells resulting in cell lysis and even apoptosis |
| ACE Inhibitor/
Ca2+ Channel Blocker | Lotrel | Amlodipine/
Benazepril | HTN | Capsules:
2.5/10, 5/10, 5/20, 5/40, 10/20, 10/40mg | Oral | 2.5/10-10/40mg
QD
Ped:N/A | Amlodipine: dihydropyridine Ca2+ channel blocker
Benazepril: nonsulfhydryl ACE inhibitor |
| Diuretic; Thiazide | HCTZ | Hydrochlorothiazide | HTN,
Edema | Tablets: 12.5, 25, 50mg
Capsule: 12.5mg | Oral | 12.5-100mg QD
(can be divided)
Ped: 1-2mg/kg/day | Electrolyte reabsorption inhibitor (resulting in increased excretion of Na+ and Cl- in equal amounts) |
| CNS Agent; Immune Suppressant | Copaxone | Glatiramer acetate | Relapsing remitting Multiple Sclerosis | Inj. Soln.:
20mg/ml | SubQ | 20mg
QD
Ped:N/A | Believed to modify immune processes or functions which are thought to be liable for MS pathogenesis. In vitro studies suggest that glatiramer specific suppressor T-cells are induced & activated in the periphery |
| ARB/Thiazide Combo | Hyzaar | Losartan/
Hydrochlorothiazide | HTN,
Prophylaxis | Tablets:
50/12.5, 100/12.5, 100/25mg | Oral | 50/12.5-100/25mg
QD
Ped:N/A | ‘sartan: angiotensin II blocker
HCTZ: increases excretion of Na+ & Cl- (diuretic/antihypertensive) |
| ARB/Thiazide Combo | Avalide | Irbesartan/
Hydrochlorothiazide | HTN | Tablets:
150/12.5, 300/12.5, 300/25 | Oral | 150/12.5-300/25mg
QD
Ped:N/A | ‘sartan: angiotensin II blocker
HCTZ: increases excretion of Na+ & Cl- (diuretic/antihypertensive) |
| Colony Stimulating Factor; Hematopoietic | Neulasta | Pegfilgrastim | Febrile neutropenia in patients with non-myeloid malignancies, Prophylaxis | Inj. Soln.: 6mg/0.6ml | SubQ | 6mg
once per chemo cycle
(don’t administer between 14 days prior to & 24 hrs after admin of chemo)
Ped:N/A | A colony stimulating factor that acts on hematopoietic cells by binding to specific cell surface receptors thereby stimulating proliferation, differentiation, commitment, and end cell functional actv’n |
| Anticoagulant; Thrombin Inhibitor | Pradaxa | Dabigatran | Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism | Capsules:
75 or 150mg | Oral | 150mg
BID
Ped:N/A | Competitive, direct thrombin inhibitor which prevents thrombus development. It inhibits both free & clot-bound thrombin as well as thrombin-induced platelet aggregation |
| ARB/Thiazide Combo | Benicar HCT | Olmesartan/
Hydrochlorothiazide | HTN | Tablets:
20/12.5, 40/12.5, 40/25mg | Oral | 20/12.5-40/25mg
QD
Ped:N/A | ‘sartan: angiotensin II blocker
HCTZ: increases excretion of Na+ & Cl- (diuretic/antihypertensive) |
| Anticoagulant; Low Molecular Weight Heparin | Lovenox | Enoxaparin | Deep Vein Thrombosis, Prophylaxis, MI | Inj. Soln.:
30mg/0.3ml, 40/0.4, 60/0.6, 80/0.8, 100mg/ml, 120/0.8, 150mg/ml | SubQ | 0.75-1.5mg/kg QD
(30-150mg per dose)
Ped: 0.5-1.5mg/kg every 12 hours | Low molecular weight heparin with anti-Factor Xa and anti-thrombin activities |
| Anticoagulant; Factor Xa inhibitor | Xarelto | Rivaroxiban | Deep Vein Thrombosis, Pulmonary embolism, Prophylaxis, Nonvalvular atrial fibrillation | Tablets:
10, 15, 20 mg | Oral | 10-20mg
QD-BID
Ped:N/A | Rivaroxaban selectively inhibits factor Xa without the need of a cofactor (eg, anti-thrombin III) for activity. |
| Anticoagulant | Coumadin; Jantoven | Warfarin | Atrial Fibrillation, Prophylaxis, Prosthetic Cardiac Valve, Thrombosis, Pulmonary Embolism | Tablets:
1, 2, 2.5, 3, 4, 5, 6, 7.5, 10mg
IV Powder for Soln. (Coumadin only): 5mg | Oral, IV | 1-10mg
QD
Ped:N/A | Blocks the regeneration of vitamin K epoxide, thus inhibiting synthesis of vitamin K-dependent clotting factors (2, 7, 9 and 10) and the anticoagulant proteins C and S |
| K+ Sparing Diuretic/Thiazide Combo | Dyazide (capsule); Maxzide (tablet) | Triamterene/
Hydrochlorothiazide | HTN,
Edema | Tablet (Maxzide): 37.5/25 or 75/50mg
Capsule (Dyazide): 37.5/25 or 50/25mg | Oral | Triamterene: 37.5-75mg
QD
HCTZ: 25-50mg QD
Ped:N/A | Triamterene: K+ sparing diuretic that inhibits reabsorption of Na+ exchange for K+ and H+ by exerting a direct effect on the distal renal tubule |
| ADP-Induced Aggregation Inhibitor;
Platelet Aggregation Inhibitor | Plavix | Clopidogrel | Prophylaxis, Thrombosis | Tablets:
75 or 300mg | Oral | 75mg
QD
Ped:N/A | Anticoagulant; prodrug that inhibits platelet aggregation by selectively & irreversibly binding to the ADP P2Y12 receptor on platelets |
| Beta-Adrenergic Blocker/Thiazide Combo; Cardioselective | Tenoretic | Atenolol/
Chlorthalidone | HTN | Tablets:
50/25 or 100/25mg | Oral | 50/25-100/25mg
QD
Ped:N/A | Atenolol: beta-blocking agent
Chlorthalidone: diuretic acting on the cortical diluting segment of the ascending limb of the loop of Henle; increase excretion of Na+ and Cl- |
